View DC engager candidates

EDC.HPVE6E7
EDC.HPVE6E7 targets the Human Papilloma Virus HPV16 E6/E7 antigens in patients with HPV-16 induced oropharyngeal cancer, the most common form of this disease accounting for more than 60% of head-and-neck cancer cases.
This DC engager candidate is currently evaluated in a Phase I/II multicentric double-blind placebo-controlled dose escalation trial (NCT06007092). The study is conducted by Gustave Roussy, Europe’s first cancer center. In December 2024, EnnoDC has presented encouraging preliminary data at ESMO IO.

EDC.PCA
EDC.PCA targets prostate cancer antigens. Prostate cancer is the second most frequent cancer in men, has the best survival rates (97% at 5 years) but the challenge of recurrence is still a major concern (up to 40% of patients). EDC.PCA is currently in preclinical development stage.
Infectious Diseases

View DC engager candidates

EDC.RBDv
EDC.RBDv targets both the ancestral Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein and a mutated version shared by several variants, including Omicron.
All marketed COVID-19 mRNA vaccines are focused on the spike region and induce neutralizing antibodies that rapidly wane. The challenge is to generate long-lasting T cell immunity which calls for vaccine boosters.
EDC.RBDv is currently evaluated in a Phase I/II clinical trial to establish its safety and immunogenicity, adjuvanted or not, as a booster in healthy volunteer (NCT06255626). This study is being conducted in collaboration with ANRS-MIE/Inserm.

EDC.PanCov
EDC.PanCov targets conserved regions of current SARS CoV-2 variants and Sarbecoviruses (the “grandparent” of SARS-CoV-2) and a highly conserved region of nucleocapsid antigens. The main objective is to generate stem cell-like memory CD8 T cells, a prerequisite for long-term protective T cell immunity.
A Phase I/II clinical trial will be launched in 2025 in collaboration with ANRS-MIE/Inserm.
EnnoDC I Contact
If you wish to contribute, collaborate or learn more about EnnoDC, we would be delighted to hear from you.
Contact